Results 41 to 50 of about 51,582 (258)

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin

BMC Complementary Medicine and Therapies, 2023
Background Cardiovascular disease and cancer are the main causes of morbidity and mortality worldwide. Studies have shown that these two diseases may have some common risk factors.
Yu-qian Li, Lu-yao Li, Xue Yang, Qi-qi Lei, Liu-yan Xiang, Yuan-ru Wang, Si-meng Gu, Ya-jun Cao, Yan Pan, Lu Tie, Xue-jun Li   +10 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.

PLoS ONE
Atorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose ...
Mariano García-Campa, Ramiro Flores-Ramírez, Sabrina Rojo-Garza, Edgar Francisco Carrizales-Sepúlveda, Diego Regalado-Ceballos, Raúl Reyes-Araiza, Neri Álvarez-Villalobos, Rene Rodríguez-Gutiérrez, José Ramón Azpiri-López   +8 more
doaj   +1 more source

Structural Changes of the Pancreas in Female Albino Rats Treated with the Atorvastatin and the Alleviating Effect of Propolis : Histological and Biochemical Study [PDF]

The Egyptian Journal of Histology
Introduction: Atorvastatin is "HMG-COA" reductase inhibitors" that is widely used for management of hyperlipidemia particularly in patients with risk of cardio and cerebrovascular stroke.
Eman sheet, zahraa taboo, waleed kasim
doaj   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Global Trends and Advances in Traumatic Brain Injury

Brain Health, EarlyView.
ABSTRACT Traumatic brain injury (TBI) remains a major global public health challenge, contributing substantially to morbidity and mortality while imposing a significant socioeconomic burden. In recent years, notable progress has been made in understanding TBI pathophysiology, classification, monitoring, and treatment.
Yuan Zhuang, Xixian Liao, Jiyao Jiang, Guoyi Gao   +3 more
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Solid dispersions of atorvastatin with Kolliphor RH40: enhanced supersaturation and improvement in a hyperlipidemic rat model

, 2023
Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fastdissolving atorvastatin ...
Guarnizo Herrero, Victor, Peña Fernández, M. Ángeles, Torrado-Santiago, Santiago, Torrado Salmerón, Carlos Félix, Torre Iglesias, Paloma Marina De La, de la Torre-Iglesias, Paloma Marina, Torrado Durán, Guillermo, Peña, M. Ángeles, Guarnizo-Herrero, Víctor, Torrado Durán, Santiago, Torrado-Salmerón, Carlos, Torrado, Guillermo   +11 more
core   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source